Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock W (2008) Clin Cancer Res 14: 7095-101 Roles for the Drs2p-Cdc50p complex in protein transport and phosphatidylserine asymmetry of the yeast plasma membrane. Chen S, Wang J, Muthusamy BP, Liu K, Zare S, Andersen RJ, Graham TR (2006) Traffic 7: 1503-17 The Essential Neo1 Protein from Budding Yeast Plays a Role in Establishing Aminophospholipid Asymmetry of the Plasma Membrane. Takar M, Wu Y, Graham TR (2016) J Biol Chem 291: 15727-39 Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D (2012) Gynecol Oncol 127: 579-86 The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Son DS, Wilson AJ, Parl AK, Khabele D (2010) Cancer Biol Ther 9: 928-35 Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Rice VM (2007) Cancer Biol Ther 6: 795-801
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.